A Phase 2, Prospective Study Of PRM-151 In Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV MF), Or Post-Essential Thrombocythemia MF (Post-ET MF)

Trial Profile

A Phase 2, Prospective Study Of PRM-151 In Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV MF), Or Post-Essential Thrombocythemia MF (Post-ET MF)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Feb 2017

At a glance

  • Drugs PRM 151 (Primary)
  • Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
  • Focus Therapeutic Use
  • Sponsors Promedior
  • Most Recent Events

    • 02 Dec 2016 Status changed from recruiting to active, no longer recruiting according to a Promedior media release.
    • 15 Jan 2016 ruxolitinib is now removed from the treatment so change in treatment, end points, inclusion-exclusion criteria, purpose. Also design of the trial changed from open to double blind, accordingly changes in patient no as per ClinicalTrials.gov record.
    • 15 Jan 2016 Planned number of patients changed from 104 to 84 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top